Skip to content

ADHD Treatment in Pediatrics and Adults: An Update

March 9, 2023 | 11 a.m – Noon

Treatment of ADHD for pediatric patients is well-established. Adult treatment of ADHD has more associated difficulties, as there are greater comorbidities. New agents have recently entered the market that pharmacists may not have reviewed in great detail. This session will discuss newer medications as an update as well as the increased risks when medications are used in adult patients.

Learning Objectives

At the completion of this activity, the participant should be able to:

  • Review the signs and symptoms of ADHD in pediatrics and adults.
  • Apply pharmacokinetic principles and drug interaction risks in determining safe and appropriate medication therapy for pediatrics and adults with ADHD
  • Examine the effect of comorbidities on pharmacotherapy decisions.


Michael Angelini, PharmD, BCPP, Professor of Pharmacy Practice at Massachusetts College of Pharmacy and Health Sciences, is a psychiatric clinical pharmacist at Saint Luke’s Hospital in New Bedford, MA and Southcoast Behavioral Health in Dartmouth, MA. Dr. Angelini is a psychopharmacology consultant for Commonwealth Pharmacy Services at the University of Massachusetts Medical School as well as a clinical consultant to primary care, community health centers, and group homes throughout New England.

Dr. Angelini has served in faculty positions for the Addiction Fellowship Program at Boston University School of Medicine, the Massachusetts School of Professional Psychology, and Harvard Medical School. Dr. Angelini holds a Master of Arts in Clinical Psychology from Boston University and a Doctor of Pharmacy from MCPHS. Board-certified in psychiatric pharmacy, Dr. Angelini has published chapters in therapeutics textbooks, study guides, and articles in peer-reviewed journals. He is a member of the American Association of Colleges of Pharmacy and the Massachusetts Pharmacists Association.

Register for 2023 Reed

Activity Number: 0026-0000-23-005-L01-P | Knowledge-Based
Topic Designator: Disease State Management/Drug Therapy
Contact Hours: 1.0